Amos Toren

Prof. Amos Toren

MD, PhD, MHA | Pediatric Hemato-Oncology & Bone Marrow Transplant Specialist

Department:

Pediatric Hemato-Oncology & BMT Division, Sheba Medical Center

Languages:

Hebrew, English

Professional Summary

Inside Sheba’s Hematology Ecosystem: Expertise Recognized by Forbes Israel

Prof. Amos Toren is a highly experienced pediatric hemato-oncologist and former Director of the Pediatric Hemato-Oncology and Bone Marrow Transplant Division at Sheba Medical Center. He is board-certified in pediatrics, general hematology, and pediatric hemato-oncology, with additional academic qualifications in genetics and healthcare management.

Prof. Toren is internationally recognized for his work in advanced therapies for pediatric cancers, particularly in the fields of immunotherapy and bone marrow transplantation. His clinical approach combines cutting-edge research with individualized treatment strategies for complex and high-risk cases.

Areas of Expertise

Pediatric oncology and hematologic malignancies

Leukemia and lymphoma in children and young adults

Bone marrow and stem cell transplantation

Immune deficiencies and chronic blood disorders

Treatment of rare and complex pediatric cancers

Advanced cellular therapies (including CAR T-cell approaches)

Education & Academic Background

MD, Faculty of Medicine, Tel Aviv University, Israel

Residency in Pediatrics, Sheba Medical Center

Residency in Hematology, Sheba Medical Center

Specialization in Pediatric Hemato-Oncology and Bone Marrow Transplantation, Hadassah Medical Center

PhD in Human Genetics, Tel Aviv University

Master of Health Administration (MHA), Recanati Business School, Tel Aviv University

Clinical & Research Experience

Prof. Toren has led one of Israel’s most advanced pediatric oncology and transplantation programs, treating both children and young adults (up to age 30) with complex malignancies.

His research focuses on:

CAR T-cell therapy for relapsed and resistant leukemias and lymphomas

cellular immunotherapy approaches (including cytokine-induced killer cells)

pediatric brain tumors

innovative targeted treatments in pediatric oncology

He is actively involved in translational research aimed at improving outcomes in treatment-resistant cancers.

International Collaboration

The department led by Prof. Toren maintains strong collaborations with leading global institutions, including:

St. Anna Children’s Hospital (Austria)

National Cancer Institute (NIH), USA

St. Jude Children’s Research Hospital, USA

Academic & Professional Roles

Former Director, Pediatric Hemato-Oncology & BMT Division

Former Head of Hematology Division, Tel Aviv University (two terms)

Member of leading international societies:

American Society of Hematology (ASH)

Children’s Oncology Group (COG)

European Society of Pediatric Hematology (ESPHI)

European Group for Blood and Marrow Transplantation (EBMT)

Center for International Blood and Marrow Transplant Research (CIBMTR)

Member, Israeli Ministry of Health Cord Blood Committee

Board Certifications

Pediatrics

Pediatric Hemato-Oncology

Bone Marrow Transplantation

Selected Publications

Immunoglobulin prophylaxis in pediatric stem cell transplantation

Overcoming resistance to PARP inhibitors in cancer therapy

Additional peer-reviewed publications in pediatric oncology and hematology

Why Patients Choose Prof. Toren

Extensive experience in complex pediatric oncology and transplantation

Expertise in advanced immunotherapies (including CAR T-cell approaches)

Strong integration of research and clinical practice

Leadership in a Top-10 globally ranked hospital

Experience with rare and treatment-resistant cases